Breaking News

Amgen Completes KAI Acquisition

Gains thyroid drug

Amgen has completion of the acquisition of KAI Pharmaceuticals based in South San Francisco. The acquisition includes KAI’s lead product candidate KAI-4169, a novel drug being studied for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis. The drug has successfully completed a Phase II trial in this indication. 
 
Amgen paid $315 million for KAI in an acquisition announced in April 2012.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters